Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT05123131 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT05123131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05123131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 1, 2022
Completion date
December 15, 2027
Enrollment
54 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma